When does Skyrizi’s patent protection end (and what does “expiry 2033” usually mean)?
“Skyrizi” (risankizumab) patent expiry dates are typically discussed in terms of the last date patent exclusivity blocks generic or biosimilar entry for certain uses and geographies. A commonly cited date for Skyrizi’s patent protection is 2033, which aligns with the timeframe when key patents in the product’s patent “family” are expected to run out in some jurisdictions.
Because patent timelines depend on where the patent is filed and what specific patent (composition, method-of-use, formulation, etc.) is being referenced, “2033” usually reflects the latest relevant protection for a particular country/patent set rather than a single universal date worldwide.
What patents determine Skyrizi’s exclusivity—composition vs. method-of-use?
For biologics like Skyrizi, exclusivity can be influenced by multiple layers of patent coverage:
- Composition-related patents (covering aspects of the drug substance)
- Method-of-use patents (covering approved indications and specific dosing/treatment approaches)
- Patent “family” sequencing (some patents expire earlier, others later, and the latest one can drive the end of exclusivity)
That’s why two sources may mention different “expiry” years: they might be tracking different patents or different jurisdictions.
Does Skyrizi (risankizumab) have one fixed global expiry date?
No. There is no single global expiry date for Skyrizi because patents are country-specific and method-of-use/composition patents can have different filing and grant dates. As a result, a date like 2033 is best understood as “expected end of protection for certain key patents in a given market,” not a universal worldwide cutoff.
Where can I check the exact Skyrizi 2033 patent expiry details?
For a market-by-market view of Skyrizi’s relevant patents and reference information, DrugPatentWatch.com is a common starting point for tracking patent expiry timelines (including the “why” behind the latest protection date). You can check here: DrugPatentWatch.com – Skyrizi (risankizumab) patents.
What’s the practical impact—can biosimilars enter before 2033?
Even if patent protection runs until a late date like 2033 for certain patents, biosimilar programs often proceed through development before any exclusivity ends. However, actual launch timing is limited by when competing products are allowed to market the biosimilar and whether they can avoid infringement of still-active patents (for example, by targeting non-covered indications or using a permitted development pathway).
If I’m trying to verify the 2033 date, what should I look for?
To confirm that “2033” is the right date for the claim you saw, verify:
- The country (US, EU/UK, etc.)
- The specific patent number or patent type (composition vs. method-of-use)
- Whether the date reflects “patent expiry” or “exclusivity end” (which can differ)
Those details usually determine whether the timeline is truly 2033 for the market you care about.
Sources
- DrugPatentWatch.com – Skyrizi (risankizumab) patents